Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation

The cardiac glycoside digoxin was identified as a potent suppressor of pyruvate kinase isoform 2-hypoxia-inducible factor-α (PKM2-HIF-1α) pathway activation in liver injury mouse models via intraperitoneal injection. We have assessed the therapeutic effects of digoxin to reduce nonalcoholic steatohe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Am J Physiol Gastrointest Liver Physiol
Päätekijät: Zhao, Peng, Han, Sheng-Na, Arumugam, Suyavaran, Yousaf, Muhammad Nadeem, Qin, Yanqin, Jiang, Joy X., Torok, Natalie Julia, Chen, Yonglin, Mankash, Mohd Salah, Liu, Junbao, Li, Jiansheng, Iwakiri, Yasuko, Ouyang, Xinshou
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Physiological Society 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6842989/
https://ncbi.nlm.nih.gov/pubmed/31411894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpgi.00054.2019
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia